# Ascletis Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ascletis-pharma

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.ascletis.com.cn
- Total disclosed funding: $100M
- Latest round: Series B (Jan 3, 2017)
- Investors on record: 6

## About

Founded in 2013 and based in Hangzhou, China, Ascletis Pharma Inc. operates as a pharmaceutical company which focuses on developing and manufacturing drugs in 3 areas, that is anti-viral (especially anti-HIV), cancer and fatty liver disease. The company has set up a production base in Shaoxing which has acquired drug production licence. The CFO, John P. Gargiulo, graduted from Duke University. It has cooperated with Roche Holding. In January 2017, Ascletis Pharma Inc. raised USD 100 million in series B financing led by returning investor C-Bridge Capital. In 2018, it was listed on the Hong Kong Stock Exchange.

Ascletis focuses on the research, development and commercialization of innovative drugs in the fields of viral diseases, metabolic diseases, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors). Products include Gonovo, Ravidasvir and ASC21, etc.

The company generates revenue by developing innovative drugs for the treatment of diseases such as antiviral, cancer and fatty liver.

## Funding rounds

- Series B, Jan 3, 2017, $100M — Goldman Sachs Asset Management, W.T.T. Investment, Focus Media Information Technology, CBC Group, Tasly Pharmaceutical Co., Ltd., Qianhai Equity Investment Fund Management

## Investors

- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- W.T.T. Investment — Series B
- Focus Media Information Technology — Series B
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B
- Tasly Pharmaceutical Co., Ltd. — Series B
- Qianhai Equity Investment Fund Management — Series B